Here Are the Facts You Need to Understand PRGO

We're taking a closer look at Perrigo Company today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved -17.4% compared to 0.3% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

  • Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed.

  • Perrigo Company has moved -17.2% over the last year compared to -18.7% for the S&P 500 -- a difference of 1.6%

  • Its trailing 12 month earnings per share (Eps) is $-0.82

  • Perrigo Company has a trailing 12 month Price to Earnings (P/E) ratio of -39.7 while the S&P 500 average is 15.97

  • Its forward earnings per share (Eps) is $3.09 and its forward P/E ratio is 10.5

  • The company has a Price to Book (P/B) ratio of 0.9 in contrast to the S&P 500's average ratio of 2.95

  • Perrigo Company is part of the Healthcare sector, which has an average P/E ratio of 13.21 and an average P/B of 4.07

  • Perrigo Company has on average reported free cash flows of $230,000,000.00 over the last four years, during which time they have grown by an an average of 44.4%

  • PRGO's gross profit margins have averaged 36.6 % over the last four years, during which time they had a growth rate of -4.0 % and a coefficient of variability of 5.1 %.

At Market Interference, our mission is to give investors access to timely and accurate data to help them make better investment decisions. subscribe to our free newsletter today to keep track of each day's market movers!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.